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compare the costs and outcomes of azacitidine (75 mg/m2 per day x 7 days every 4
weeks) vs. decitabine (45 mg/m2 per day x 3 days every 6 weeks) from the perspec-
tive of SUS. METHODS: We developed a Markov model to determine the cost-
effectiveness (CE) and 3-year budget impact of introducing AZA in the Brazilian
market. Patients considered were classified with IPSS Int 1, Int 2 and High risk. The
model considered progression to acute myelogenous leukemia (AML) and death as
the major outcomes of treatment. Outcomes, costs and epidemiological data were
obtained from a systematic review of literature and public sources. The costs of
adverse events and progressive disease were also included. A sensitivity analysis
was performed to test the robustness of the results. The currency conversion used
was BR$ 1.8: US$1.0. RESULTS: The cost effectiveness analysis showed better re-
sults for AZA compared to DEC resulting in lower costs and improved outcomes in
terms ofmortality rates and progression to AML. Over a 3-year time period, the use
of AZA was associated with a savings of BR$85,000 (US$45,000) compared to DEC.
Assuming that AZA would be given to 50% of patients with MDS in Brazil, it would
have a budgetary impact of BR$45,000 000 (US$25,000,000) for the public health care
system SUS. CONCLUSIONS:When compared to DEC, AZA showed improved out-
comes and lower costs as a treatment option for MDS in the Brazilian public health
system.
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COMPARING HEALTH CARE RESOURCE USE, COSTS AND ADVERSE EVENTS
AMONG LUNG CANCER PATIENTS TREATED WITH STANDARD
CHEMOTHERAPY WITH OR WITHOUT AN ANGIOGENESIS INHIBITOR: A
RETROSPECTIVE DATABASE STUDY
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OBJECTIVES: To estimate resource use, costs, and adverse events (AEs) among lung
cancer (LC) patients on standard chemotherapy with versus without an angiogen-
esis inhibitor (AGI) as adjunctive therapy. METHODS: Using Thompson Reuters
MarketScan®ResearchDatabase, patientswith a diagnosis code indicating primary
LC between 2005 and 2009 and at least one claim for an FDA approved AGI (bevaci-
zumab) within 8 days of chemotherapywere identified (AGI cohort). These patients
were matched 1:1 by demographics, cancer characteristics, and previous chemo-
therapy failure (30 days without chemotherapy) to patients on chemotherapy
with no claims for an AGI (No-AGI cohort). Patients were followed for 1 month.
All-cause per-patient-per-month (PPPM) resource use (inpatient, ER, and outpa-
tient), costs (in 2010 USD), and the prevalence of AEs were assessed. RESULTS: A
total of 766 patients were identified for each cohort (mean age 57.5 years, 47.9%
female). Mean follow-up was 10.4 and 11.6 months in the AGI and No-AGI cohorts.
All components of resource usewere similar between cohorts. All-cause total PPPM
cost was higher for the AGI cohort ($16,972 vs. $11,950 PPPM), primarily due to
higher outpatient infusion costs ($7,703 vs. $1,423). Over 52% of patients in each
cohort had 1 AE, and there were no statistically-significant differences in the
prevalence of AEs between groups. Themost common AEs were infusion reactions
(40.6% in AGI vs. 39.7% in No-AGI), dyspnea, (38.1% vs. 43.0%), nausea (37.6% vs.
33.8%), dehydration (32.9% vs. 34.1%), chest pain (28.9% vs. 31.5%), anemia (26.1%
vs. 24.4%), neutropenia (24.9% vs. 24.7%), thromboembolic events (17.2% vs. 20.6%),
and hemorrhage (15.4% vs. 12.7%). CONCLUSIONS: Prevalence of AEs was not sig-
nificantly different among LC patients on chemotherapy with and without an AGI.
Costs were higher in the AGI cohort, due to higher infusion costs. Future studies of
the cost-effectiveness of AGIs in LC patients based on real-world data are war-
ranted.
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ASSOCIATED TREATMENT COSTS IN THE PRIVATE MEXICAN HEALTH CARE
SYSTEM
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OBJECTIVES:We performed an indirect comparison of efficacy and safety data for
two combination chemotherapy regimens (pemetrexed/cisplatin [PC] and bevaci-
zumab/cisplatin/gemcitabine [BCG]) approved for the first-line treatment of ad-
vanced, non-squamous non-small cell lung cancer (NSCLC). Our objectives were to
compare the survival outcomes and approximate mean incremental costs in
México for these two approved regimens using data from two phase III trials with a
common comparator (cisplatin/gemcitabine [CG]). METHODS: An indirect treat-
ment comparison was conducted using the Bucher method. One study compared
CG with BCG and included two doses of bevacizumab, but only the data for the 7.5
mg/kg dose of bevacizumabwas included in our analysis because this dose ismore
commonly used for NSCLC in México. The cost analysis included the estimated
costs of chemotherapy and costs related to the treatment of grade 3 or 4 adverse
events. Total chemotherapy drug costs were based on the mean number of cycles
of chemotherapy delivered in the two studies. Costs were calculated in 2011 Mex-
ican pesos and converted to US dollars. RESULTS: Significantly fewer patients ex-
perienced a grade3 adverse event with PC than BCG (risk difference: -10.50%; 95%
confidence interval [CI]: -18.4 to -2.71, p0.008). Overall survival was not signifi-
cantly different for PC vs BCG (hazard ratio [HR]0.87, 95% CI: 0.69 to 1.10, p0.242),
although in the individual trials PC had a significant survival advantage over CG
(HR0.84; 95% CI: 0.74 to 0.96, p0.011) while BCG (7.5 mg/kg bevacizumab) had no
survival advantage (HR0.93; 95% CI: 0.78 to 1.11. p0.420). The total estimated
costs were $20212 lower for PC than BCG. The cost savings for the PC regimenwere
predominantly due to lower pharmacy-related drug costs ($10501 vs $30121).
CONCLUSIONS: PChad lower estimated costs and less serious toxicity compared to
BCG and produced at least comparable survival outcomes.
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DESCRIPTIVE COSTS OF CHEMOTHERAPY TREATMENT FOR STAGE 3 AND
STAGE 4 COLON CANCER
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OBJECTIVES: The National Cancer Institute (NCI) estimates that cancer accounted
for approximately $124.57 billion dollars in direct costs in the United States in 2010.
NCI provides costs estimates on the initial, continuing and last ‘phase of care’ but
does not provide a breakdown by stage. This study aims to describe the costs
associated with stage 3 (S3) and stage 4 (S4) colon cancer (CC). METHODS: Data
from 1997-2005 of the Surveillance, Epidemiology, and End-Result-Medicare data-
set was used for this analysis. Individuals includedwere those diagnosed as having
AJCC S3 or S4 CC. Analyses excluded individuals whowere not eligible forMedicare
Parts A and B or those insured by Medicare HMO. Areas under the curve (AUC) for
direct medical costs were summed over a 40 week period, from time of CC diagno-
sis. Costs contributed were from beneficiaries who died from S3 and S4 CC and
were ever treated with chemotherapy. Costs were summed for S3 and S4 individ-
uals with at least 26 weeks of initial chemotherapy treatment. RESULTS: These
analyses identified 3549 individuals with S3 CC and 8194 individuals with S4 CC.
Over the 40 week observation period, the AUC for S3 and S4 CC was $52,145, and
$45,106, respectively. Meanweekly costs peaked at week 31 for S3 CC ($3425) and at
week 29 for S4 CC ($1,725). Among S3 and S4 individuals with at least 26 weeks of
initial chemotherapy treatment, the AUC was $35,890 for S3 CC and $49,871 for S4
CC. CONCLUSIONS: Among individuals who died with S3 or S4 CC and were ever
treated with chemotherapy, the costs associated with S3 cancer exceed those of S4
cancer over the 40 week observation period. Among those with at least 26 weeks of
initial chemotherapy and treatment, S3 chemotherapy treatment is less expensive
than S4 chemotherapy treatment.
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OBJECTIVES: This retrospective claims analysis aimed to compare erythropoiesis-
stimulating agent (ESA) dosing patterns and costs in chemotherapy-induced ane-
mia (CIA) hospital outpatients. METHODS: Electronic records from the Premier
hospital database (2006Q1-2011Q1) were used to identify outpatients aged 18
years that had a diagnosis for cancer, received chemotherapy during hospitaliza-
tion, and received epoetin alfa (EPO) or darbepoetin alfa (DARB).Exclusion criteria
were: a diagnosis of chronic kidney disease, diagnosis of myelodysplastic syn-
drome, receipt of renal dialysis, or receipt of both ESAs. The observation period
consisted of the outpatient continuous ESA episode, defined as the period fromfirst
to last outpatient visit with ESA use without a gap of more than one calendar
month between ESA visits. The ESA dose ratio (Units EPO: mcg DARB) was calcu-
lated using the mean cumulative dose of EPO and DARB. ESA treatment costs were
determined using cumulative dose and December 2010 wholesale acquisition
costs. RESULTS: A total of 7413 outpatient ESA episodes (EPO: 3979; DARB: 3434)
were identified. The EPO group had a lower proportion of females versus the DARB
group (61.7% vs. 67.7%, respectively; P0.001), however, EPO and DARB groups had
a similar mean age (62.0 vs. 61.8 years, respectively; P0.560) and duration of out-
patient episode (2.3months for both, P0.738). Themean cumulative dosewas EPO
212,752 Units and DARB 998mcg, resulting in a dose ratio (Units EPO: mcg DARB) of
213:1. Correspondingmean ESA treatment costs were higher for DARB than for EPO
(EPO: $3,223 vs. DARB: $5,352, P0.001). CONCLUSIONS: In this analysis of CIA
hospital outpatient records, a dose ratio (Units EPO: mcg DARB) of 213:1 was ob-
served. Mean ESA treatment costs were observed to be approximately 66% higher
for the DARB group than for the EPO group.
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EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN
CHEMOTHERAPY-INDUCED ANEMIA INPATIENTS
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OBJECTIVES: This retrospective analysis aimed to compare erythropoiesis-stimu-
lating agent (ESA) dosing patterns and costs in chemotherapy-induced anemia
(CIA) inpatients.METHODS: Electronic records from the Premier hospital database
(2006Q1-2011Q1) were used to identify inpatients aged 18 years that had a diag-
nosis for cancer, received chemotherapy during hospitalization, and received epo-
etin alfa (EPO) or darbepoetin alfa (DARB). Exclusion criteria were: a diagnosis of
chronic kidney disease, diagnosis of myelodysplastic syndrome, receipt of renal
dialysis, or receipt of both ESAs. The observation period consisted of the inpatient
stay. The ESA dose ratio (Units EPO: mcg DARB) was calculated using the mean
cumulative dose of EPO and DARB. ESA treatment costs were determined using
cumulative dose and December 2010wholesale acquisition costs. RESULTS:A total
of 20,132 inpatient stays (EPO: 15,221; DARB: 4,911) were identified. The EPO group
was older than the DARB group (65.0 vs. 63.7 years, respectively; P0.001), had a
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lower proportion of females (53.8% vs. 55.7%, respectively; P0.019), and had a
longer mean length of stay (LOS) (13.2 vs. 12.1 days, respectively; P0.001). The
mean cumulative dose was EPO 57,248 Units and DARB 211mcg, resulting in a dose
ratio (Units EPO: mcg DARB) of 271:1. Mean ESA treatment costs were higher for
DARB than for EPO (EPO: $867 vs. DARB: $1,130; P0.001). CONCLUSIONS: In this
analysis of CIA inpatient records, a dose ratio (Units EPO: mcg DARB) of 271:1 was
observed. Mean ESA treatment costs were observed to be approximately 30%
higher for the DARB group than for the EPO group despite a longer LOS for the EPO
group.
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COST COMPARISON OF ERLOTINIB VERSUS GENERIC DOCETAXEL IN SECOND-
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OBJECTIVES: Lung cancer is the leading cause of cancer deaths worldwide (1.38
million cancer deaths, 18.2% of the total) and of cancermorbidity (1.61million new
cases, 12.7% of all new cancers). Currently only three second-line (2L) non-small
cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union,
the chemotherapies pemetrexed and docetaxel as well as the Epidermal Growth
Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) erlotinib. These therapy
alternatives have shown a comparable efficacy (survival benefit). In the past cost
comparisons showed that erlotinib was less costly compared to docetaxel, which
itself was cheaper than pemetrexed. Nowadays erlotinib (and docetaxel) are still
less expensive than pemetrexed; but docetaxel lost patent protection (basic com-
pound patent) at the end of 2010, so the docetaxel drug costs have decreased
rapidly, which poses the question of whether erlotinib still is the least costly ther-
apy alternative in 2L NSCLC. METHODS: Italy has been selected exemplarily to
compare the total therapy costs, estimated by combining country-specific drug
costs, administration costs and adverse event costs of erlotinib and generic do-
cetaxel in 2LNSCLC therapy. Sensitivity analyses on central input parameters have
been performed. RESULTS: The total costs of treating one patient with erlotinib
therapy of €5121 are lower than the docetaxel costs of €6699 for the Italian health-
care setting. Although the drug costs of erlotinib are higher than generic docetaxel
(incremental €3770), the costs of intravenous chemotherapy administration (incre-
mental -€4510) and the costs of adverse event therapy (incremental -€837) lead to
higher total therapy costs of docetaxel compared to the EGFR TKI therapy erlotinib.
CONCLUSIONS: The cost comparison findings for Italy show that erlotinib is still
the less costly therapy alternative in 2L NSCLC. These results were robust to
changes of central input parameters and robust to further potential price decreases
for docetaxel.
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PHYSICIAN-SPECIALTY COST DIFFERENCES OF TREATING NON-MELANOMA
SKIN CANCER (NMSC): AN UPDATE
Chirikov VV, Stuart B, Zuckerman IH
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OBJECTIVES: Studies have previously reported specialty-related cost differences
for the treatment of non-melanoma skin cancer (NMSC) but without attempting to
establish a causal relationship. This study addresses if specialty-related cost dif-
ferences in the management of NMSC still persist, controlling for potential
confounders.METHODS:Using a previously validatedmodel for episode of care for
NMSC, patients diagnosed with NMSC were identified in part B of the Medicare
Current Beneficiary Survey claims from 2005-07. Physician specialty exposure dur-
ing an episode was defined in three approximately mutually exclusive categories:
1) General Practitioner/Family Medicine/Internal Medicine/General Surgeon/Oth-
ers; 2) Dermatologist; 3) Otolaryngologist/Plastic Surgeon. A log-linear regression
modelwas built of treatment cost as dependent variable and physician exposure as
independent variable controlling for treatment settings, patient demographics,
health status, treatment procedure, tumor size and tumor location that may con-
tribute to differences in the cost of NMSC management. RESULTS: Over years
2005-2007, 1449 unique episodes of care for the management of NMSC were iden-
tified, 24% of which were not treatment-related episodes. Analyzing treatment-
related episodes only, significantmedian cost differences across the three specialty
categories were observed: $297.4 for generalist/other specialist, $441.5 for derma-
tologist, and $672.8 for otolaryngologist/plastic surgeon. In regression analysis,
compared to dermatologist, having seen a generalist/other specialist was associ-
atedwith 29.6% lower costs (P0.001)while having seen an otolaryngologist/plastic
surgeon was associated with 24.6% higher costs (P0.001). Those living in metro
areas were likely to have 11% (P0.04) higher costs. Treating a tumor in the facial
area was associatedwith 17% (P0.001) higher costs than a tumor in the trunk area
of the body.CONCLUSIONS:This study suggests that controlling for demographics,
health status, and treatment predictors, unaccounted specialty-related cost differ-
ences still exist in the management of NMSC and require further investigation.
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OBJECTIVES: To describe the demographic and clinical characteristics and comor-
bidities of colorectal cancer (CRC) patients and to evaluate the disease-specific
expenditures (i.e., insurer-paid costs and patient-incurred out-of-pocket [OOP] ex-
penses) incurred by CRC patients with one, two, and three ormore lines of therapy.
METHODS: Data were from the Thomson Reuters MarketScan® Research Databases.
The analysis population included patients 18 years with incident CRC during
2005-2009who utilized one ormore lines of CRC therapy (defined by a 90-day gap in
treatment or initiation of a new regimen). Demographic characteristics, health
status indices, and comorbidities were measured at baseline and/or during follow-
up. Expenditure data (i.e., paid amounts of adjudicated claims) were collected for
patients while on therapy. OOP expenses were coinsurance and copayments. Av-
erage per-patient monthly expenditures (2009 US dollars) were calculated in com-
posite for all patients from initiation of first-line therapy through follow-up, and
also disaggregated by each line of therapy. RESULTS: Among 13,670 CRC patients,
9,224 (67.5%) had exactly one line of therapy, 2,836 (20.7%) had exactly two lines,
and 1,610 (11.8%) had three ormore lines of therapy. Total per-patient expenditures
for first-line therapy averaged $12,067 per month, but increased to $13,312 for
patients transitioning to second-line therapy, and to $14,651 for patients transi-
tioning to third-line therapy. Monthly OOP expenses were a small (about 2%) con-
tributor to total costs, ranging from $241, $246, and $238 by respective lines of
therapy. Total monthly expenditures for patients covered by commercial insur-
ance were substantially (50%) higher than for patients covered by Medicare sup-
plemental insurance. CONCLUSIONS: Ranging from about $12,000 to $15,000 per
month by increasing lines of therapy, direct costs of CRC present a significant
economic burden to health plans and self-insured employers. Patient-borne OOP
expenses are relatively small but meaningful contributors to the overall financial
burden imposed by CRC.
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PATIENT SURVIVAL, HEALTH CARE UTILIZATION, AND COSTS IN MEDICARE
PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO MATCHED
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OBJECTIVES: To compare survival and healthcare utilization and costs among
Medicare patients with acute myeloid leukemia (AML) versus a matched cohort of
Medicare patients without cancer.METHODS: Patients aged 65 years in the Sur-
veillance, Epidemiology, and End Results (SEER) cancer registry with a new AML
diagnosis from January 1, 1997 to December 31, 2007 were identified (first diagnosis
termed “index”). Patients were required to have 6 months Medicare Part A and B
benefits pre-index and no managed care enrollment post-index. Patients were ex-
cluded if they had another tumor in SEER pre-index. Medicare patients without
cancer were identified and matched up to 5 to 1 based on age (5 years), gender,
race, geographic location, and common comorbidities. Patientswere followed from
index (or index of the corresponding AML patient among controls) to death or
database end (i.e., December 31, 2007). Study measures included median survival
and health care utilization and costs. Generalized linear models were undertaken
to estimate adjusted costs. RESULTS: A total of 6,888 selected AML patients were
matched to 22,346 controls. Among AML patients and controls respectively, mean
(SD) age was 78.3(7.2) and 72.7(6.7) years, median survival was 2.6 and 131.7
months, mean (SD) total follow-up costs were $90,395($104,228) and $26,900
($41,840), and mean (SD) average monthly follow-up costs were $26,990 ($30,719)
and $269 ($468). The largest proportion of costs was hospitalization-related in both
cohorts (74% and 42% of total, respectively). The cost difference between cohorts
was mainly attributable to hospitalizations ($56,314 difference), followed by out-
patient visits ($3,382 difference) (both p0.001). AML patients and controls had
approximately the same number of emergency department, outpatient hospital,
and home health visits. Regression analyses found AML patients accrued $74,177
more in costs than controls (p0.001). CONCLUSIONS: While AML patients had
shorter median survival, they accrued 3 times more costs, mainly driven by hospi-
talizations. This indicates a substantial economic burden incurred by AML patients
to Medicare.
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ECONOMIC BURDEN ASSOCIATED WITH ADVERSE EVENTS IN PATIENTS WITH
METASTATIC RENAL CELL CARCINOMA
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients
receiving targeted therapies for first-line treatment of metastatic renal cell carci-
noma (mRCC).METHODS:A retrospective study utilizing the IntegratedHealthcare
Information Services (IHCIS) claims data from 2000 to 2009 was conducted. Study
subjects were aged 18 years, had mRCC, and received 1st line treatment with
targeted therapies. AEs of interest comprised abdominal pain, back pain, diarrhea,
dyspnea, extremity pain, fatigue/asthenia, hand-foot syndrome, hypertension,
lymphopenia, nausea/vomiting, neutropenia, and proteinuria. Healthcare encoun-
ters for AEs were based on ICD-9-CM diagnosis/procedure codes on healthcare
claims. Costs of AEs were examined over a 30-day period, beginning with the date
of first mention of each AE, and were estimated based on the difference in total
costs between patients with and without events; nonevented patients similarly
were assigned a “shadow” index date. Direct drug costs of targeted agents were
excluded from the analysis. Multivariate generalized linear models (GLM) with a
log-link function and gamma response probability distribution were utilized to
control for differences in baseline characteristics between patients with and with-
out evidence of adverse events. RESULTS: A total of 533 patients were included in
this analysis: 418 patients with adverse events and 115 patients without adverse
events. Baseline characteristics were generally similar between patients in the two
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